NMRA Earnings & Financial Statements
Neumora Therapeutics, Inc. Common Stock
$0.53
+$0.03(+5.08%)
35
Overall
60
Value
36
Tech
10
Quality
Market Cap
$98.70M
Volume
2.99M
52W Range
$0.48 - $1.85
Target Price
$6.14
NMRA earnings and financial statements: Neumora Therapeutics, Inc. Common Stock's income statement, balance sheet and cash flow statement, annual and quarterly.
NMRA Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating income | -$241.16M | -$263.46M | -$252.10M | -$136.28M | -$237.32M |
| EBITDA | -$236.31M | -$248.70M | -$251.43M | -$131.12M | - |
| Net income | -$236.93M | -$243.79M | -$235.93M | -$131.71M | -$237.31M |
| EPS (diluted) | $-1.45 | $-1.53 | $-3.63 | $-4.81 | $-10.84 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $191.05M | $316.97M | $496.19M | $426.23M | $429.30M |
| Total liabilities | $87.18M | $29.91M | $27.12M | $29.40M | $24.66M |
| Shareholders’ equity | $103.87M | $287.06M | $469.08M | $396.84M | $404.64M |
| Cash and equivalents | $182.53M | $142.15M | $374.04M | $240.94M | $409.25M |
| Long-term debt | $54.73M | - | $1.85M | $5.07M | $996.0K |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$206.44M | -$182.94M | -$163.28M | -$114.90M | -$75.42M |
| Capital expenditure | $200.0K | - | -$117.0K | - | - |
| Free cash flow | -$206.44M | -$182.94M | -$163.40M | -$115.41M | -$76.24M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | NMRA | $0.53 | +5.1% | 2.99M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Neumora Therapeutics, Inc. Common Stock Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW